Wise... when armed with Ph2 knowledge about tumor mapping, pk/pd data, the multiple "types" and their responses, Menon will be able to construct a laser focused Ph3 that could be beautiful (i.e. hit all endpoints), assuming that K works as we all hope. In addition, looks like we may have more than one "combo" trial coming up with K.

I agree... "breakthrough" yes, but don't skip.